Patents by Inventor Yoko Mullen

Yoko Mullen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10092387
    Abstract: An implantable medical device, a method of manufacturing, and a method of use are described. The implantable medical device includes an absorption bag connected by a cannula to a discharge bag. The implantable medical device also includes a reservoir external to the discharge bag and attached to a surface of the discharge bag. At least a portion of the absorption bag and at least a portion of a bottom surface of the reservoir are permeable to a predefined class of small molecules, such as molecular oxygen. The reservoir can retain live cells that rely on the small molecules for survival and growth. Based on concentration of the small molecules, the small molecules permeate into the absorption bag and are transported to the discharge bag for permeation into the reservoir, thereby providing a supply of the small molecules to the live cells.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: October 9, 2018
    Assignees: California Institute of Technology, City of Hope
    Inventors: Yu-Chong Tai, Dongyang Kang, Hirotake Komatsu, Henry K. Lin, Yoko Mullen
  • Publication number: 20180030537
    Abstract: p53-upregulated modulator of apoptosis (PUMA) is a biomarker associated with islet cell health. If PUMA is low, islet cells are typically healthy. If PUMA is high, islet cells are typically unhealthy or dying. PUMA may be measured by either measuring its nucleic or amino acid. PUMA mRNA may be induced by TNF-? stimulation in a time- and dose-dependent manner and ? cell apoptosis is induced through a mitochondrial pathway. TNF-? significantly inhibited glucose-induced preproinsulin precursor mRNA synthesis. Such ? cell stress signaling in human islets indicates overall state of islet health and, ultimately, the risk of onset and/or degree of severity of both type 1 and type 2 diabetes mellitus.
    Type: Application
    Filed: August 7, 2017
    Publication date: February 1, 2018
    Inventors: Yoko MULLEN, Masato MITSUHASHI, Keiko OMORI
  • Patent number: 9758826
    Abstract: p53-upregulated modulator of apoptosis (PUMA) is a biomarker associated with islet cell health. If PUMA is low, islet cells are typically healthy. If PUMA is high, islet cells are typically unhealthy or dying. PUMA may be measured by either measuring its nucleic or amino acid. PUMA mRNA may be induced by TNF-? stimulation in a time- and dose-dependent manner and ? cell apoptosis is induced through a mitochondrial pathway. TNF-? significantly inhibited glucose-induced preproinsulin precursor mRNA synthesis. Such ? cell stress signaling in human islets indicates overall state of islet health and, ultimately, the risk of onset and/or degree of severity of both type 1 and type 2 diabetes mellitus.
    Type: Grant
    Filed: June 17, 2011
    Date of Patent: September 12, 2017
    Assignees: City of Hope, Hitachi Chemical Research Center, Inc., Hitachi Chemical Co., Ltd.
    Inventors: Yoko Mullen, Masato Mitsuhashi, Keiko Omori
  • Publication number: 20170086963
    Abstract: An implantable medical device, a method of manufacturing, and a method of use are described. The implantable medical device includes an absorption bag connected by a cannula to a discharge bag. The implantable medical device also includes a reservoir external to the discharge bag and attached to a surface of the discharge bag. At least a portion of the absorption bag and at least a portion of a bottom surface of the reservoir are permeable to a predefined class of small molecules, such as molecular oxygen. The reservoir can retain live cells that rely on the small molecules for survival and growth. Based on concentration of the small molecules, the small molecules permeate into the absorption bag and are transported to the discharge bag for permeation into the reservoir, thereby providing a supply of the small molecules to the live cells.
    Type: Application
    Filed: September 23, 2016
    Publication date: March 30, 2017
    Applicants: California Institute of Technology, City of Hope
    Inventors: Yu-Chong Tai, Dongyang Kang, Hirotake Komatsu, Henry K. Lin, Yoko Mullen
  • Patent number: 9289500
    Abstract: The disclosure provides for saccharide-peptide based hydrogels, the functionalization of the saccharide-peptide based hydrogels with one or more biological agents, and the encapsulation of one or more biological materials and/or pharmaceutical agents in the hydrogels. The disclosure further provides for the use of the saccharide-peptide based hydrogels in treating a disease or disorder in a subject.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: March 22, 2016
    Assignees: The Regents of the University of California, City of Hope
    Inventors: Zhibin Guan, Yoko Mullen, Sophia W. Liao
  • Publication number: 20140242123
    Abstract: The disclosure provides for saccharide-peptide based hydrogels, the functionalization of the saccharide-peptide based hydrogels with one or more biological agents, and the encapsulation of one or more biological materials and/or pharmaceutical agents in the hydrogels. The disclosure further provides for the use of the saccharide-peptide based hydrogels in treating a disease or disorder in a subject.
    Type: Application
    Filed: February 21, 2014
    Publication date: August 28, 2014
    Inventors: Zhibin Guan, Yoko Mullen, Sophia W. Liao
  • Publication number: 20110318751
    Abstract: p53-upregulated modulator of apoptosis (PUMA) is a biomarker associated with islet cell health. If PUMA is low, islet cells are typically healthy. If PUMA is high, islet cells are typically unhealthy or dying. PUMA may be measured by either measuring its nucleic or amino acid. PUMA mRNA may be induced by TNF-? stimulation in a time- and dose-dependent manner and ? cell apoptosis is induced through a mitochondrial pathway. TNF-? significantly inhibited glucose-induced preproinsulin precursor mRNA synthesis. Such ? cell stress signaling in human islets indicates overall state of islet health and, ultimately, the risk of onset and/or degree of severity of both type 1 and type 2 diabetes mellitus.
    Type: Application
    Filed: June 17, 2011
    Publication date: December 29, 2011
    Inventors: Yoko MULLEN, Masato Mitsuhashi, Keiko Omori
  • Patent number: 5919703
    Abstract: A method, a solution and a chamber for the preparation and storage of pancreatic islets. The method includes contacting a pancreas with a warm collagenase solution, digesting the pancreas in the warm collagenase solution to form warm digest, adding cold preservative solution to the warm digest, agitating the warm digest/cold preservative solution at a temperature between about 0.degree. and 15.degree. C., to thereby further digest the partially digested pancreas included in the warm digest, to form cold digest and collecting liquid from the cold digest to form isolated islets. The cold preservative solution and a pancreatic islet preservative solution of the present invention include D-mannitol, K-lactobionate and a buffer.
    Type: Grant
    Filed: June 6, 1996
    Date of Patent: July 6, 1999
    Assignee: The Regents of the University of California
    Inventors: Yoko Mullen, Takashi Kenmochi
  • Patent number: 5679565
    Abstract: A method, a solution and a chamber for the preparation and storage of pancreatic islets. The method includes contacting a pancreas with a warm collagenase solution, digesting the pancreas in the warm collagenase solution to form warm digest, adding cold preservative solution to the warm digest, agitating the warm digest/cold preservative solution at a temperature between about 0.degree. and 15.degree. C., to thereby further digest the partially digested pancreas included in the warm digest, to form cold digest and collecting liquid from the cold digest to form isolated islets. The cold preservative solution and a pancreatic islet preservative solution of the present invention include D-mannitol, K-lactobionate and a buffer.
    Type: Grant
    Filed: April 10, 1995
    Date of Patent: October 21, 1997
    Assignee: The Regents of the University of California
    Inventors: Yoko Mullen, Takashi Kenmochi